A history of the role of the hERG channel in cardiac risk assessment (Q39443606)

12 September 2017

A history of the role of the hERG channel in cardiac risk assessment (English)

1 reference

12 September 2017

0 references

David Rampe

1

1 reference

PubMed ID

23538024

12 September 2017

Arthur M Brown

series ordinal

2

1 reference

PubMed ID

23538024

12 September 2017

language of work or name

1 reference

26 March 2013

1 reference

Journal of Pharmacological and Toxicological Methods

12 September 2017

1 reference

12 September 2017

68

1 reference

12 September 2017

13-22

1 reference

12 September 2017

1

1 reference

K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Effects of fluoroquinolones on HERG currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Ether-à-go-go encodes a voltage-gated channel permeable to K+ and Ca2+ and modulated by cAMP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Astemizole-induced ventricular arrhythmias: an unexpected cause of convulsions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Electrophysiology of human cardiac cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Pentamidine reduces hERG expression to prolong the QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Cardiotoxic effect with convulsions in terfenadine overdose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Molecular determinants of pentamidine-induced hERG trafficking inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Role of the Kv4.3 K+ channel in ventricular muscle. A molecular correlate for the transient outward current.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

The Structure of the Potassium Channel: Molecular Basis of K+ Conduction and Selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Mechanisms of arsenic-induced prolongation of cardiac repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Structure and function of voltage-dependent sodium channels: comparison of brain II and cardiac isoforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

'Legal highs'--novel and emerging psychoactive drugs: a chemical overview for the toxicologist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Medicinal chemistry of hERG optimizations: Highlights and hang-ups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Crystal structure and mechanism of a calcium-gated potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Cardiac ion channel effects of tolterodine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Towards in silico identification of the human ether-a-go-go-related gene channel blockers: discriminative vs. generative classification models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Machine learning algorithms for the prediction of hERG and CYP450 binding in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Cardiac Na currents and the inactivating, reopening, and waiting properties of single cardiac Na channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Pentamidine-induced long QT syndrome and block of hERG trafficking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Alfuzosin delays cardiac repolarization by a novel mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Cisapride-induced long QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

QTc interval prolongation in patients on long-term methadone maintenance therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine block HERG potassium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

A structural basis for drug-induced long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Inhibition of HERG potassium channels by cocaethylene: a metabolite of cocaine and ethanol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Principles of safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

QTc interval prolongation by d-propoxyphene: what about other analgesics?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Selective IK blockade as an antiarrhythmic mechanism: effects of UK66,914 on ischaemia and reperfusion arrhythmias in rat and rabbit hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

QT prolongation and arrhythmia suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

7 January 2021

HERG1 channelopathies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Predicting drug-hERG channel interactions that cause acquired long QT syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Activators of cation channels: potential in treatment of channelopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

The inward rectification mechanism of the HERG cardiac potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Drug block of the hERG potassium channel: insight from modeling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Pharmacology, structure and function of cardiac L-type Ca(2+) channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Electrophysiologic characterization of a novel hERG channel activator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Chronic inhibition of cardiac Kir2.1 and HERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Inhibition of HERG potassium channels by the antimalarial agent halofantrine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

hERG K(+) channels: structure, function, and clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Electrophysiological effects of labetolol on rabbit atrial, ventricular and Purkinje cells, in normoxia and hypoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Delayed rectifier channels in human ventricular myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Integrated risk assessment and predictive value to humans of non-clinical repolarization assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Rapid and slow components of delayed rectifier current in human atrial myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

A distinct potassium channel polypeptide encoded by the Drosophila eag locus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

A family of potassium channel genes related to eag in Drosophila and mammals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Gating of inwardly rectifying K+ channels localized to a single negatively charged residue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Cardiotoxic effects of astemizole overdose in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Psychotropic drugs, cardiac arrhythmia, and sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Progesterone impairs human ether-a-go-go-related gene (HERG) trafficking by disruption of intracellular cholesterol homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Mechanism of block and identification of the verapamil binding domain to HERG potassium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.005

10.1016/J.VASCN.2013.03.005

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference

PubMed ID

23538024